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anjay K. Gandhi, MD, FACC, Renato M. Santos, MD, FACC,
illiam C. Little, MD, FACC
inston-Salem, North Carolina
bjectives This study sought to evaluate trends in vascular complications after diagnostic cardiac
atheterization (CATH) and percutaneous coronary intervention (PCI) from the femoral artery from
998 to 2007.
ackground Vascular complications have been recognized as an important factor in morbidity after
ATH and PCI. Whether strategies to reduce vascular complications performed from the femoral ar-
ery in the past decade have improved the safety of these procedures, however, is uncertain.
ethods A total of 35,016 consecutive diagnostic cardiac catheterization (n  20,777) and percuta-
eous coronary intervention procedures (n  14,239) performed via a femoral access at a single site
Wake Forest University Baptist Medical Center) between 1998 and 2007 were evaluated. Annual
ates of vascular complications were evaluated. Covariate effects on the risk of vascular complica-
ions were evaluated by logistic regression and risk-adjusted trend analysis.
esults Overall, the incidence of any vascular complication decreased signiﬁcantly for CATH, 1.7%
ersus 0.2%, and PCI, 3.1% versus 1.0%, from 1998 to 2007, both p  0.001 for trend. Favorable
rends in procedural covariates affecting vascular complications were mainly responsible for the de-
rease in the incidence of vascular complications, including fewer closure device failures and use of
maller sheath sizes.
onclusions In this large, single-center, contemporary observational study, the safety of CATH and
CI performed from the femoral artery improved signiﬁcantly from 1998 to 2007. Reductions in the
revalence of adverse procedural factors contributed to the decrease in the incidence of vascular
omplications, suggesting that strategies to reduce vascular complications can be effective in im-
roving the safety of these procedures. (J Am Coll Cardiol Intv 2008;1:317–26) © 2008 by the
merican College of Cardiology Foundation
rom the Wake Forest University School of Medicine, Section of Cardiology, Winston-Salem, North Carolina.anuscript received November 21, 2007; revised manuscript received February 6, 2008, accepted March 15, 2008.
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318ecent studies have identified bleeding after diagnostic
ardiac catheterization (CATH) and percutaneous coronary
ntervention (PCI) procedures (1–4), particularly retroper-
toneal bleeding (5,6), as a significant source of morbidity
nd mortality after these procedures. Although not all of the
leeding can be directly attributed to complications at the
rocedure access site, access site complications remain a
ignificant factor in post-procedural bleeding (7–9). Al-
hough medical and PCI treatments have been modified to
inimize access site bleeding from anticoagulant and anti-
latelet therapies (8,10), their use as pre-procedural treat-
ent has increased substantially in the past decade, which
ould increase the risk of vascular complications. At the
ame time, strategies aimed at reducing femoral artery access
ite complications, such as use of fluoroscopy to guide
emoral artery access (11), utilization of vascular closure
evices (VCDs), and use of smaller sheath sizes, have been
ntroduced into practice. Whether the awareness of the
mportance of access site complications on overall proce-
ural outcomes (12–14), or utilization of VCDs (15,16) and
maller sheath sizes (12,17,18), or changes in medical and
PCI practice (8,10) have had an
effect on the incidence of vascu-
lar complications in the past de-
cade is not clear. Accordingly,
we assessed trends in the inci-
dence of vascular complications
after CATH and PCI proce-
dures performed from the fem-
oral artery from 1998 to 2007.
We also evaluated trends in pa-
tient and procedural covariates
that may have affected the risk of
eveloping a vascular complication from these procedures.
ethods
ll patients at our institution undergoing percutaneous
ATH and PCI were evaluated for this study, which was
pproved by the Institutional Review Board. A total of
3,157 patients underwent 35,016 procedures from January
998 to March 2007. Choice of the access site was at the
iscretion of the physician performing the case. Preference
as for femoral artery access, with radial and brachial access
btained when femoral access could not be obtained; 22,846
atients underwent 34,556 procedures using the femoral
pproach, 79 patients underwent 105 procedures from the
adial artery, and 232 patients underwent 355 procedures
rom the brachial approach, and form the basis for this
tudy. Data from some of these patients have been included
n a prior publication (19).
For patients undergoing procedures via femoral artery
ccess, CATH patients received unfractionated heparin
bbreviations
nd Acronyms
ATH  diagnostic cardiac
atheterization
P  glycoprotein
C  manual compression
CI  percutaneous
oronary intervention
CD  vascular closure
evicefter sheath insertion at the discretion of the cardiologist Terforming the procedure. For patients undergoing proce-
ures via radial or brachial access, 3,000 to 5,000 units of
eparin were given immediately after sheath insertion.
nticoagulation after sheath insertion for PCI patients was
btained using unfractionated heparin with a target acti-
ated clotting time of 200 to 250 s if used in conjunction
ith glycoprotein (GP) IIb/IIIa inhibitors, or 250 to 300s
therwise (10), or bivalirudin per standard protocol (8).
atients in the study received GP IIb/IIIa receptor inhibi-
ion also according to usual protocol with abciximab or
ptifibatide (20). Post-PCI patients were treated with aspi-
in (81 to 325 mg/day) and clopidogrel (300 or 600 mg as a
oading dose followed by 75 mg/day) if stents were placed.
ccess site management. The method of arterial access
anagement was chosen by the cardiologist performing the
rocedure. Manual compression was obtained by physicians
erforming the procedure, or trained catheter laboratory and
ursing unit personnel. The VCD placement was per-
ormed by physicians trained in their use. Brachial artery
heaths were removed immediately after the procedure, and
emostasis was obtained by manual compression. Radial
rtery sheaths also were removed immediately after the
rocedure with hemostasis obtained using Hemoband com-
ression (Hemoband Corp., Portland, Oregon). The VCDs
ere placed only after a femoral arteriogram was performed
ia the arterial sheath. Patients did not undergo arterial
losure with a VCD if: 1) the arteriotomy site was below the
emoral bifurcation; 2) the common femoral artery was 5
m in diameter; 3) extensive calcification or plaque forma-
ion was present in the common femoral artery; or 4)
xtensive scar tissue was present at the access site. Closure
as performed using a variety of VCDs at the discretion of
he cardiologist performing the procedure including Angi-
seal (St. Jude Medical, St. Paul, Minnesota), Vasoseal
Datascope Corp., Mahwah, New Jersey), Quikseal (Sub-Q
nc., San Clemente, California), Duett (Vascular Solutions,
inneapolis, Minnesota), and Perclose and Starclose (Ab-
ott Vascular, Redwood City, California) (20). All sheaths
ere removed soon after the procedure as outlined below. In
atients in whom arterial closure was not performed in the
aboratory, the sheath was pulled when the activated clotting
ime was 180 s in patients who received heparin or 2 h
fter the infusion of bivalirudin was completed. Use of a
opical thrombin hemostatic patch (D-STAT Dry, Vascular
olutions) to facilitate manual compression was introduced
n April 2004 and used on all subsequent manual compres-
ions (21). Ambulation was initiated 2 h after the VCD was
laced or D-STAT was used, and 6 h after manual
ompression alone.
Access site evaluation was routinely done after the pro-
edure and before discharge. The nurse caring for the
atient examined the access site for possible vascular com-
lications and recorded the findings in the nurses’ notes.
he physicians caring for the patient also examined the
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319ccess site and recorded the observations in the chart. Before
ospital discharge, the patient’s chart was abstracted by a
linical research nurse, including the nurses’ notes, the
edical record, and all tests performed during the hospital-
zation. The presence and type of vascular complications
ere recorded in an institutional database (20). Outcomes
easures collected conformed to the American College of
ardiology database definitions for vascular complications
22). Minor vascular complications were defined as any of
he following: hematoma 10 cm, arteriovenous fistulae, or
seudoaneurysm. Major vascular complications were de-
ned as death caused by vascular complications, vascular
epair, major vascular bleeding (3 g hemoglobin decrease
ecause of access site bleeding or retroperitoneal bleeding),
essel occlusion, or loss of pulse (20,22).
tatistical methods. Descriptive statistics (means and stan-
ard deviation of continuous factors, frequency counts and
elative frequencies of categorical factors) were calculated
nd compared for statistical significance across vascular
omplication groups using the Wilcoxon rank sum test for
ontinuous factors and chi-square testing for categorical
actors. Annual trends of baseline covariates and vascular
omplications were tested by the Cochran-Armitage trend
est. Univariate associations between clinical and procedural
ovariates and vascular complications were examined using
he Wald chi-square test. Logistic regression modeling was
sed to assess multivariate predictors of vascular complica-
ions using generalized estimating equations to account for
epeated measures (23). All statistically significant (p 
.10) univariate predictors of vascular complications were
onsidered for selection in the multivariate models. All
reviously known clinically significant independent predic-
ors of vascular complications (i.e., sheath size) were re-
ained in all models. A final predictive model for vascular
omplications was constructed and used to calculate the
verage risk-adjusted probability of vascular complications
or each year, stratified by closure method, procedure, and
heath size. The SAS statistical software package (version
.1, SAS Institute, Cary, North Carolina) was used for all
tatistical analysis.
esults
he vast majority of procedures were performed via femoral
rtery access (99%), with 0.8% performed via the brachial
rtery, and 0.2% performed via the radial artery. Access site
anagement was accomplished by manual compression in
6% of CATH and 50% of PCI procedures, whereas VCDs
ere used in 24% of CATH and 50% of PCI procedures.
he baseline clinical and procedural covariates of all CATH
nd PCI patients with and without vascular complications
re shown in Table 1. Meaningful differences in the 2
roups included older age, female gender, and higher body iurface area in those with vascular complications compared
ith those without vascular complications. Meaningful
rocedural differences in the 2 groups included procedure
ype (PCI vs. CATH) and larger sheath size in those with
ompared to those without vascular complications.
There were 453 (1.3%) vascular complications after fem-
ral artery access, 0 (0.0%) after radial artery access, and 16
4.5%) after brachial artery access, p  0.05 versus femoral
rtery access. The incidence and trend of specific major and
inor vascular complications for CATH and PCI proce-
ures performed from the femoral artery access are shown in
able 2. There was a significant decrease in both major and
inor vascular complications over the course of the study, p
0.001 for trend for both, although the decrease was
reater for minor than for major vascular complications.
ength of stay increased an average of 4 days for those with
6.7  12.1 days) compared to those without (2.7  5.8
ays) vascular complications, p  0.001.
redictors of vascular complications. Independent predictors
f vascular complications for the entire study group and for the
ubgroups undergoing CATH and PCI are shown in Table 3.
ailed closure with a VCD, female gender, history of renal
ailure, peripheral vascular disease, larger sheath sizes, and
n-laboratory heparin use (CATH only) were the strongest
ndependent predictors of increased vascular complications
ver the entire study period. Conversely, successful use of a
CD was the strongest independent predictor of lower vascu-
ar complications. Use of bivalirudin was infrequent and was
ot associated with an increased or decreased risk of vascular
omplications. Similarly, the use of a brachial or radial artery as
ccess site was infrequent and was not associated with an
ncreased or decreased risk of vascular complications.
emporal trends in the incidence of vascular complications.
he incidence of any vascular complications after femoral
rtery access by year of procedure, procedure type, and
losure method for procedures performed is plotted in
igure 1. The incidence of vascular complications decreased
ignificantly over the course of the study, p  0.001 for
rend, both for CATH and PCI procedures. The number of
ATH and PCI procedures performed from the radial and
rachial arteries was small, and the incidence of vascular
omplications over the course of the study was not evalu-
ted. The incidence of vascular complications for both
anual compression and VCDs also decreased significantly
ver the course of the study period, p  0.01 for trend, for
oth CATH and PCI procedures. The incidence of vascular
omplications by year and VCD type is shown in Figure 2.
or both Angioseal and Perclose, there was a significant
rend toward a decrease in vascular complications over the
tudy period, most notable for PCI procedures. The inci-
ence of vascular complications for each individual sheath
ize over the course of the study for both CATH and PCI
s plotted in Figure 3. There was a trend toward a decrease
n vascular complications for all sheath sizes for both
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 1 , N O . 3 , 2 0 0 8
J U N E 2 0 0 8 : 3 1 7 – 2 6
Applegate et al.
Trends in Vascular Complications
320Table 1. Baseline Patient and Procedural Characteristics by Vascular Complication Outcomes
Characteristic
Vascular Complications
(n  470)
No Vascular Complications
(n  34,546) p Value
Demographics
Age, yrs 66  13 62  12 0.001
Female gender 56% 39% 0.001
Medical history
Heart failure class III or IV 14% 11% 0.027
Current smoker 27% 30% 0.151
Diabetes mellitus 29% 30% 0.559
Hypercholesterolemia 59% 65% 0.004
Hypertension 79% 75% 0.032
History of renal failure 9% 5% 0.001
Peripheral vascular disease 16% 10% 0.001
Previous percutaneous coronary intervention 24% 31% 0.002
Body mass index, m2, median (interquartile range) 1.87 (1.70–2.04) 1.97 (1.80–2.13) 0.001
Indication for procedure
Acute coronary syndrome 76% 63% 0.001
Myocardial infarction within 7 days 32% 22% 0.001
Stable angina 7% 12% 0.001
Atypical chest pain, no angina 17% 24% 0.001
Diagnostic catheterizations 44% 60% 0.001
Arterial access location 0.001
Femoral 95% 98%
Brachial 5% 1.2%
Radial 0% 0.4%
Sheath size, F 7.5 1.0 5.8 0.6 0.001
Medications
Bivalirudin in-laboratory 0% 0.1% 0.663
Lovenox in-laboratory 0% 0.4% 0.370
Glycoprotein IIb/IIIa inhibitor in-laboratory 9% 6% 0.035
Aspirin at discharge* 88% 76% 0.229
Clopidogrel at discharge* 59% 23% 0.001
Closure method 0.125
Manual compression 81% 76%
Vascular closure device 19% 24%
Failed closure† 7% 1% 0.001
Percutaneous coronary interventions 56% 40% 0.001
Arterial access location 0.009
Femoral 98% 99%
Brachial 2% 0.7%
Radial 0% 0.2%
Sheath size, F 7.7 1.0 6.0 0.5 0.001
Medications
Bivalirudin in-laboratory 5% 6% 0.547
Lovenox in-laboratory 1% 2% 0.183
Glycoprotein IIb/IIIa inhibitor in-laboratory 93% 92% 0.629
Aspirin at discharge* 80% 92% 0.012
Clopidogrel at discharge* 77% 91% 0.003
Closure method 0.019
Manual compression 58% 50%
Vascular closure device 42% 50%
Failed closure† 14% 2% 0.001*Data collected starting March 2005 (diagnostic cardiac catheterization n 3,856; percutaneous coronary intervention n 2,778). †Femoral compression device required to achieve hemostasis.
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321ATH and PCI, with significant differences in 6-F CATH
nd 10-F PCI. A plot of the risk of vascular complications
or all CATH and PCI procedures is depicted in Figure 4,
djusted for covariate effects as identified in the multivariate
nalysis (Table 3). Over the course of the study, the adjusted
isk decreased significantly, p  0.01 for trend for both
ATH and PCI, although this was most notable for PCI
rocedures. Qualitatively similar outcomes were observed
or both the CATH and the PCI subgroups.
rends in factors affecting rates of vascular complications.
here were minimal changes in the risk-adjusted rate of
ascular complications of individual sheath sizes for both
Table 2. Vascular Complications by Year of Procedure
Complication
1998
(n  4,284)
1999
(n  4,423)
2000
(n  4,329)
2001
(n  3,876)
Any vascular complication 94 (2.2%) 73 (1.7%) 67 (1.6%) 58 (1.5%)
Major vascular complication 45 (1.1%) 42 (1.0%) 33 (0.8%) 30 (0.8%)
Retroperitoneal bleeding 16 (0.4%) 19 (0.4%) 19 (0.4%) 10 (0.3%)
Other major bleeding 16 (0.4%) 14 (0.3%) 9 (0.2%) 11 (0.3%)
Occlusion 3 (0.1%) 6 (0.1%) 0 (0%) 1 (0.03%)
Loss of distal pulse 6 (0.1%) 6 (0.1%) 3 (0.1%) 5 (0.1%)
Vascular surgery 15 (0.4%) 7 (0.2%) 9 (0.2%) 7 (0.2%)
Vascular death 3 (0.1%) 1 (0.02%) 2 (0.1%) 0 (0%)
Minor vascular complication 72 (1.7%) 44 (1.0%) 48 (1.1%) 42 (1.1%)
Pseudoaneurysm 21 (0.5%) 10 (0.2%) 10 (0.2%) 10 (0.3%)
AV ﬁstulae 8 (0.2%) 2 (0.1%) 8 (0.2%) 3 (0.1%)
Hematoma 10 cm 47 (1.1%) 36 (0.8%) 32 (0.7%) 34 (0.9%)
n number of procedures. *Cochran-Armitage trend test.
Table 3. Multivariate Analysis of Vascular Complications
All Procedures
Odds Ratio
(95% CI) p Va
Increased risk
Failed closure 7.38 (5.24–10.39) 0.0
Female gender 1.84 (1.44–2.34) 0.0
History of renal failure 1.69 (1.21–2.36) 0.0
Peripheral vascular disease 1.50 (1.15–1.94) 0.0
Glycoprotein IIb/IIIa inhibitor in-laboratory 1.44 (1.10–1.89) 0.0
Bivalirudin in-laboratory* 1.42 (0.78–2.58) 0.2
Hypertension 1.29 (1.00–1.67) 0.0
Sheath size, F 1.29 (1.17–1.41) 0.0
Age, yrs 1.02 (1.01–1.03) 0.0
Heparin in-laboratory†
Decreased risk
Body surface area, m2 0.59 (0.34–1.03) 0.0
Vascular closure device used 0.65 (0.53–0.81) 0.0
Previous intervention 0.75 (0.60–0.93) 0.0
Hypercholesterolemia 0.80 (0.65–0.98) 0.0
*Not included in CATH-onlymultivariatemodel because of lownumbers in CATH-only patients andnin-laboratory heparin used, therefore only examined in CATH-only model. CATH diagnostic cardiac cathATH and PCI (Table 4). There did seem to be a
rogressive increase in the adjusted risk of vascular compli-
ations, however, for increasing sheath sizes for both
ATH and PCI. A categorical analysis of the risk of
ascular complications by sheath size and procedure type is
hown in Figure 5. For CATH, the risk of vascular
omplications was lower for 4-F sheath size compared with
ll other sheath sizes. For PCI, the risk of vascular compli-
ations of 6- and 7-F sheaths were similar, odds ratio 1.09
95% confidence interval 0.70 to 1.10). However, the risk of
ascular complications of 8-, 9-, and 10-F sheaths were all
igher than for 6-F sheaths, although the 95% confidence
02
,854)
2003
(n  3,550)
2004
(n  3,495)
2005
(n  3,224)
2006
(n  3,195)
2007
(n  786)
Trend*
p Value
.1%) 35 (1.0%) 42 (1.2%) 25 (0.8%) 31 (1.0%) 4 (0.5%) 0.001
.5%) 20 (0.6%) 21 (0.6%) 11 (0.3%) 24 (0.8%) 1 (0.1%) 0.001
.3%) 7 (0.2%) 15 (0.4%) 6 (0.2%) 15 (0.5%) 0 (0%) 0.241
.2%) 8 (0.2%) 3 (0.1%) 1 (0.03%) 7 (0.2%) 0 (0%) 0.001
.03%) 3 (0.1%) 1 (0.03%) 1 (0.03%) 0 (0%) 0 (0%) 0.056
.1%) 5 (0.1%) 1 (0.03%) 3 (0.1%) 0 (0%) 1 (0.1%) 0.084
.2%) 5 (0.1%) 8 (0.2%) 4 (0.1%) 7 (0.2%) 0 (0%) 0.127
%) 2 (0.1%) 1 (0.03%) 2 (0.1%) 1 (0.03%) 0 (0%) 0.749
.8%) 22 (0.6%) 26 (0.7%) 17 (0.5%) 15 (0.5%) 3 (0.4%) 0.001
.3%) 7 (0.2%) 10 (0.3%) 10 (0.3%) 5 (0.2%) 2 (0.3%) 0.115
.1%) 6 (0.2%) 6 (0.2%) 5 (0.2%) 1 (0.03%) 0 (0%) 0.468
.5%) 11 (0.3%) 13 (0.4%) 3 (0.1%) 10 (0.3%) 2 (0.3%) 0.001
CATH Only PCI
Odds Ratio
(95% CI) p Value
Odds Ratio
(95% CI) p Value
9.15 (4.75–17.63) 0.001 6.93 (4.63–10.36) 0.001
1.70 (1.19–2.41) 0.003 1.99 (1.42–2.78) 0.001
2.35 (1.52–3.62) 0.001 1.12 (0.65–1.95) 0.682
1.65 (1.14–2.39) 0.008 1.30 (0.90–1.89) 0.167
1.65 (1.00–2.72) 0.048 0.94 (0.35–2.58) 0.911
0.90 (0.28–2.87) 0.859
1.63 (1.08–2.45) 0.019 1.09 (0.78–1.50) 0.622
1.69 (1.40–2.02) 0.001 1.19 (1.06–1.35) 0.004
1.02 (1.01–1.04) 0.002 1.01 (1.00–1.03) 0.035
1.40 (1.04–1.88) 0.025
0.81 (0.38–1.74) 0.588 0.45 (0.21–0.96) 0.039
0.65 (0.44–0.97) 0.035 0.65 (0.50–0.84) 0.001
0.84 (0.59–1.21) 0.354 0.70 (0.52–0.93) 0.015
0.68 (0.50–0.93) 0.014 0.91 (0.69–1.19) 0.474
lar complications in the procedureswith direct thrombin inhibitor used.†All PCI patients had some20
(n  3
41 (1
20 (0
11 (0
6 (0
1 (0
3 (0
6 (0
0 (0
31 (0
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322imits were wider for 9- and 10-F sheaths and did not reach
tatistical significance.
To further examine potential reasons for the decrease in
ascular complications observed during the course of the
tudy, we also evaluated the annual frequency of the
ovariates shown in the multivariate analysis to affect the
isk of vascular complications. In 2007, compared with
998, closure device failure decreased and body surface area
BSA) increased, both of which would be associated with a
ower potential risk of vascular complications in 2007
ompared with 1998 (Table 5). Use of smaller sheath sizes
ncreased for both CATH and PCI. Changes in other
ovariates among the CATH and PCI patients from 1998
o 2007 were small.
iscussion
n this large, contemporary, single-center experience, the
ncidence of vascular complications decreased from 1998 to
007 for both CATH and PCI procedures performed from
he femoral artery. The decrease in vascular complications
Figure 1. Any Vascular Complications by Procedure and Closure Method
Graph depicting the incidence of any vascular complication by procedure type
tion; MC  manual compression; PCI  percutaneous coronary intervention; V
Figure 2. Any Vascular Complications by Vascular Closure DeviceGraph of the incidence of any vascular complication by procedure type and vascularccurred for both manual compression and VCD manage-
ent of the femoral artery access site. A decrease in minor
ascular complications, predominantly a decrease in hema-
oma 10 cm, accounted for the greatest proportion of the
verall decrease in the incidence of vascular complications.
he incidence of major vascular complications also de-
reased, although the incidence of retroperitoneal bleeding
as low and unchanged over the study period. These
bservations provide strong evidence that CATH and PCI
erformed from the femoral artery have become safer
rocedures in the past decade.
We evaluated patient and procedural factors that influ-
nced the risk of vascular complications, as well as their
revalence, over the decade of the study. Adverse patient
actors included female gender, history of renal failure or
eripheral vascular disease, and low BSA. Failed closure
ith a VCD, in-laboratory heparin use (CATH only), and
arger sheath size were the strongest independent predictors
f increased vascular complications, whereas successful use
f a closure device and larger BSA were the strongest
closure method from 1998 to 2007. CATH  diagnostic cardiac catheteriza-
vascular closure device.andclosure device from 1998 to 2007. Abbreviations as in Figure 1.
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323redictors of a decrease in vascular complications. There did
ot seem to be a substantial change in the prevalence of
dverse patient variables during the course of the study.
owever, as a result of changes in practice during CATH
nd PCI procedures, there was a substantial decrease over
he study period in the prevalence of adverse procedural
ariables including less use of in-laboratory heparin during
ATH, fewer failed VCDs, and use of smaller, less harmful
heath sizes. Thus, implementation of procedural strategies
o reduce vascular complications after femoral artery access
eemed to have resulted in improved safety of CATH and
CI procedures.
Multiple studies have identified factors associated with an
ncrease in the risk of vascular complications during CATH
nd PCI procedures performed from the femoral artery. In
he American College of Cardiology National Cardiovas-
ular Disease Registry female gender, emergency proce-
ures, PCI (vs. CATH), sheath size, and renal failure were
ound to be independently predictive of increased vascular
omplications (24,25). Female gender, emergency proce-
ures, and a femoral artery access site at or above the inferior
Figure 3. Any Vascular Complications by Sheath Size
Graph of the incidence of any vascular complication for each sheath size for P
Figure 4. Risk-Adjusted Incidence of Vascular Complications
Graph of the incidence of any vascular complication by procedure type and cl
Abbreviations as in Figure 1.pigastric artery were associated with an increased risk of
etroperitoneal bleeding (5,6). We have previously reported
hat female gender was a strong risk factor for an increased
isk of vascular complications during CATH and PCI from
femoral artery access site, but that the risk had decreased
rom 1998 to 2005 (26). The results of these prior studies,
oupled with our observations, suggest that strategies focus-
ng on reducing or eliminating adverse procedural practices
ay improve the safety of CATH and PCI procedures
erformed after femoral artery access.
We also performed a detailed analysis of the risk-adjusted
ncidence of vascular complications per sheath size used over
he past 10 years. Although most clinicians would state that
maller sheath sizes are safer during CATH and PCI, there
re few large studies directly examining this issue
17,18,27). Moreover, studies developing models to predict
ascular complications after CATH or PCI have not in-
luded sheath size in their study or predictive models
12,14,28). Our study indicates that the incidence of vascu-
ar complications decreased with smaller sheath sizes for
oth CATH and PCI. Interestingly, the risk-adjusted rate
CATH from 1998 to 2007. Abbreviations as in Figure 1.
method from 1998 to 2007 adjusted for patient and procedural confounders.osure
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324f vascular complications for any given sheath size remained
ssentially unchanged over the course of the study. These
bservations taken together provide strong evidence that
witching to smaller sheath sizes, which seem to be inher-
ntly safer, resulted in improved safety.
Recent randomized clinical trials of PCI outcomes, pri-
arily performed from femoral artery access, have shown a
ecrease in the rates of bleeding with the use of bivalirudin
ompared with heparin and a GP IIb/IIIa inhibitor (7). We
id not observe a decrease in the incidence of vascular
omplications with bivalirudin, although it was used in only
% of PCI cases. Similarly, use of the radial artery as access
or CATH and PCI procedures has been associated with
ower rates of access site complications compared with the
ame procedures performed from the brachial or femoral
rtery (29,30). Radial artery use was infrequent in our
xperience. In spite of the fact that we did not observe any
ascular complications with procedures performed from the
Figure 5. ORs of Vascular Complications by Categorical Comparison of
Sheath Sizes
Univariate analysis of the odds ratio of any vascular complication stratiﬁed
by procedure and sheath size for the entire study period. CI  conﬁdence
Table 4. Risk-Adjusted Incidence of Vascular Complications by Year, Proce
Procedure, Sheath Size 1998 1999 2000 2001
Diagnostic cardiac catheterization
4-F 0.6% 0.7%
5-F 1.3% 0.7% 0.7% 0.6%
6-F 1.0% 1.0% 1.0% 1.0%
7-F 1.4% 1.3% 1.3% 1.2%
Percutaneous coronary intervention
6-F 1.2% 1.7% 1.1% 1.4%
7-F 3.4% 1.6% 1.5% 1.5%
8-F 2.4% 2.2% 1.9% 1.8%
9-F 2.8% 2.5% 2.5% 2.5%
10-F 3.7% 2.8% 2.5%
*Spearman correlation test.m
interval; OR  odds ratio; other abbreviations as in Figure 1.adial artery, the numbers were too small to provide a
eaningful comparison with complications occurring after
emoral artery access. The decrease in rates of access site
omplications observed with use of the radial artery (29,30),
owever, makes it one of the modifiable procedural variables
hat can reduce rates of vascular complications in the cardiac
atheterization laboratory.
tudy limitations. This study is subject to the limitations of
bservational studies. The incidence of any vascular com-
lication after diagnostic CATH or PCI in this study was
ow, approximately 1.5%. This incidence is somewhat less
han has been generally reported (1.5% to 4.0%) (15) and
ikely reflects narrower definitions of vascular complications
sed in this study (22). Reporting biases because of varia-
ions in clinical follow up may have influenced the apparent
ower incidence of vascular complications, but are unlikely
o have biased the results in favor of one access site
anagement strategy over another. Multivariate analysis
djusted for baseline differences in measured covariates,
ut did not correct for unmeasured covariates that may
ave confounded the results. The effect of factors not
ssessed or measured in this study may have been respon-
ible for the changes observed in this study. Finally, we did
ot evaluate vascular complications after discharge from the
ospital.
linical implications. There has been a growing awareness of
he importance of peri-procedural CATH and PCI bleed-
ng, particularly because of access site complications. Focus
n the complications has increased as the safety of the
ardiac procedure itself has improved. Over the past decade,
e implemented multiple strategies to reduce vascular
omplications in the cardiac catheterization laboratory from
rocedures performed from the femoral artery, including use
f fluoroscopy to guide femoral artery access (11), downsiz-
ng sheath sizes (12,17,18), use of VCDs (15,16), and
Type, and Sheath Size
2002 2003 2004 2005 2006 2007
Trend*
p Value
0.6% 0.7% 0.7% 0.7% 0.6% 0.5% 0.905
0.7% 0.7% 0.6% 0.6% 0.6% 0.6% 0.002
0.9% 0.9% 0.9% 0.9% 0.9% 0.8% 0.133
1.2% 0.9% 1.1% 1.1% 1.3% 0.4% 0.418
1.3% 1.3% 1.3% 1.2% 1.1% 1.3% 0.932
1.6% 1.5% 1.6% 1.6% 1.5% 1.5% 0.467
2.1% 2.1% 1.9% 2.1% 2.0% 2.2% 0.014
2.5% 3.5% 0.893
0.044dureinimizing heparin use during CATH procedures. All of
t
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325hese strategies seemed to contribute to a decrease in the
isk of vascular complications after femoral artery access.
ur findings should provide reassurance that CATH and
CI have become safer procedures with respect to femoral
rtery access site complications. Moreover, our findings
hould provide impetus for transitioning to use of smaller
heath sizes, particularly for CATH procedures, as well as
ncorporating procedural strategies that reflect optimal use
f anticoagulants.
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Table 5. Trends in Annual Prevalence of Clinical and Procedural Covariates
1998 1999 2000 2001
Clinical variables
Age, yrs 62  12 63  12 63  12 63 
Female gender 37% 39% 38% 38%
History of renal failure 4% 4% 4% 6%
Peripheral vascular disease 9% 10% 10% 12%
Body surface area, m2, median 1.95 1.95 1.96 1.96
Interquartile range 1.80–2.11 1.79–2.11 1.80–2.12 1.80–2
Procedural variables
Brachial, radial access 1.0% 1.1% 1.2% 1.5%
Vascular closure device use, CATH 18% 31% 32% 22%
Vascular closure device use, PCI 58% 67% 63% 52%
Failed closure, CATH 1.0% 1.3% 1.6% 1.1%
Failed closure, PCI 6.2% 3.6% 1.8% 1.5%
Bivalirudin in-laboratory 0% 0% 0% 0%
Glycoprotein IIb/IIIa inhibitor
in-laboratory
37% 41% 45% 46%
Sheath size, CATH
4-F 0% 0% 2% 16%
5-F 0.4% 3% 10% 9%
6-F 92% 84% 82% 73%
7-F 7% 13% 4% 2%
Sheath size, PCI
6-F 0.5% 1% 5% 10%
7-F 0.4% 3% 28% 54%
8-F 44% 50% 41% 25%
9-F 37% 32% 21% 8%
10-F 17% 13% 6% 3%
p value corresponds to Cochran-Armitage trend test for frequency (%) variables; Spearman correla
CATH diagnostic cardiac catheterization; PCI percutaneous coronary intervention.EFERENCES
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